Accelerated Phase Chronic Myelogenous Leukemia Terminated Phase 2 Trials for Deferasirox (DB01609)

IndicationStatusPhase
DBCOND0028985 (Accelerated Phase Chronic Myelogenous Leukemia)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01159067Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadSupportive Care